Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
Patients with newly diagnosed, pathologically confirmed NK/T-cell lymphoma of stage III-IV
treated with XCOPL regimen. 3 weeks for a cycle, with a total of 6-8 cycles.